European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) SARS-CoV-2 Antibody Study Protocol. Covid-19
NCT04726137 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 906
Last updated 2024-09-20
Summary
Scientific knowledge about the COVID-19 pandemic and the virus that is causing it (SARS-CoV-2) is developing rapidly, and the investigators have a clearer idea of the population groups who are at higher risk of becoming infected, having serious illness, and dying. However, less is known about COVID-19 in children, adolescents and young adults living with HIV. It is not yet known whether, or how, HIV affects people's risk of being infected with the virus or becoming ill. This study aims to find out whether children and adolescents living with HIV have had the COVID-19 virus, even if they did not have symptoms and did not realise it at the time.
When a person is infected with a virus, their immune system fights the infection. As a result, they produce proteins called antibodies, and it may take a few weeks for enough antibodies to be made to be detected by a blood test. These antibodies may help protect the person from getting the same infection again. This study wants to find out how many children and adolescents living with HIV across Europe and South Africa have antibodies to the COVID-19 virus. It wants to see if the proportion with antibodies is different in younger children compared to older adolescents and young adults, and whether it varies between different countries.
Children and adolescents with HIV regularly attend hospital outpatient appointments, and during these appointments blood samples may be taken to monitor their health. This study will invite these patients to be tested for antibodies to the COVID-19 virus during their routine visit. The participants will be asked a few short questions about COVID-19 diagnoses in their household and other risk factors for exposure to the virus, and it will collect information on their HIV, medications and any other illnesses they may have. At their next routine clinic visit, approximately 6 months later, it will test them again for antibodies. Testing twice will let see how the percentage of children, adolescents and young adults with antibodies to the COVID-19 virus has changed over time. In South Africa, HIV-uninfected adolescents from a similar socioeconomic background to those living with HIV and recruited to the study will be invited to join this study, which will allow us to compare the prevalence of antibodies across the two groups.
The information from this study will help scientists and healthcare workers care for children, adolescents and young adults living with HIV during the ongoing COVID-19 epidemic in the best possible way. Participants may be given their test results, together with information about what the result means, depending on the usual practice within their clinic.
Conditions
- Sars-Cov2 Antibodies in Children and Adolescents Living With HIV
Sponsors & Collaborators
-
Centre Hospitalier Universitaire Saint Pierre
collaborator OTHER -
University of Athens
collaborator OTHER -
University of Cape Town
collaborator OTHER -
Hospital General Universitario Gregorio Marañon
collaborator OTHER -
Hospital Sant Joan de Deu
collaborator OTHER -
Great Ormond Street Hospital for Children NHS Foundation Trust
collaborator OTHER -
Guy's and St Thomas' NHS Foundation Trust
collaborator OTHER -
Northern Care Alliance NHS Group
collaborator OTHER -
University Hospital Birmingham NHS Foundation Trust
collaborator OTHER -
Imperial College Healthcare NHS Trust
collaborator OTHER -
King's College Hospital NHS Trust
collaborator OTHER -
St George's University Hospitals NHS Foundation Trust
collaborator OTHER -
CHIPS+ Cohort
collaborator OTHER -
University College, London
collaborator OTHER -
PENTA Foundation
lead NETWORK
Principal Investigators
-
Intira J Collins, PhD · [email protected]
Eligibility
- Max Age
- 24 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-10-14
- Primary Completion
- 2022-07-09
- Completion
- 2022-07-09
Countries
- Belgium
- Greece
- South Africa
- Spain
- Ukraine
- United Kingdom
Study Locations
More Related Trials
-
Elizabeth Glaser Pediatric AIDS Foundation Maternal Events and Pregnancy Outcomes (MEP Project)A Multi-site Protocol
NCT00639145 ·Status: COMPLETED
-
Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial
NCT00936195 ·Status: WITHDRAWN ·Phase: PHASE3
-
Cohort of Young Adults Infected With HIV Since Birth or During Childhood
NCT01269632 ·Status: COMPLETED ·Phase: NA
-
Prevalence of Hepatitis C Virus Infection in HIV-Infected Children
NCT00037076 ·Status: COMPLETED
-
A Prospective Cohort of Children With HIV Infection
NCT00476606 ·Status: COMPLETED
-
Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs
NCT00013871 ·Status: COMPLETED ·Phase: NA
-
IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women
NCT00955968 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Pre-Exposure Prophylaxis (PrEP) in Pregnant and Breastfeeding Women
NCT03902418 ·Status: COMPLETED
-
Evaluation of the Population-level Impact of PMTCT Option B+ in Zimbabwe
NCT03388398 ·Status: COMPLETED
-
Evaluating the Safety and Immune Response to Two Pneumococcal Vaccines in HIV-Infected Pregnant Women
NCT01443117 ·Status: WITHDRAWN ·Phase: PHASE2
-
Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries
NCT01061151 ·Status: COMPLETED ·Phase: PHASE3
-
Does Provision of Point of Care CD4 Technology and Early Knowledge of CD4 Levels Affect Early Initiation and Retention on Anti-retroviral Treatment (ART) in HIV Positive Pregnant Women in the Context of Option B+ for PMTCT?
NCT02070900 ·Status: UNKNOWN ·Phase: NA
-
Prenatal and Postnatal Studies of Interventions for Prevention of Mother-To-Child Transmission
NCT00028145 ·Status: COMPLETED
-
UNCPM 22314 - Pregnancy, Infant and Maternal Health Outcomes Study
NCT06158126 ·Status: RECRUITING ·Phase: PHASE4
-
Pertussis Immunization During Pregnancy & HIV Infection
NCT03519373 ·Status: COMPLETED
-
Prospective Observational Cohort Study on Mother to Child Transmission HIV1/HIV2 and Prevention
NCT03235310 ·Status: UNKNOWN
-
Development of Resistance Mutations in Pregnant HIV-positive (+) Women Following Perinatal Antiretroviral Therapy in Israel
NCT00197366 ·Status: TERMINATED
-
Cardiometabolic Health of Children Exposed to Anti-retroviral Therapy (ART) in Utero
NCT04763668 ·Status: UNKNOWN
-
Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA)
NCT00334256 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women
NCT02717494 ·Status: COMPLETED ·Phase: PHASE2
-
Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics
NCT00702013 ·Status: COMPLETED
-
Long-Term Clinical, Immunologic, and Virologic Profiles of Children Who Received Early Treatment for HIV
NCT05154513 ·Status: COMPLETED
-
Pediatric Enhanced Surveillance Study
NCT02043769 ·Status: COMPLETED
-
Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection
NCT02778204 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
NCT06517693 ·Status: RECRUITING ·Phase: PHASE1